Cidara Therapeutics (CDTX) Equity Ratio: 2017-2025
Historic Equity Ratio for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to 0.81.
- Cidara Therapeutics' Equity Ratio rose 14.33% to 0.81 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.81, marking a year-over-year increase of 14.33%. This contributed to the annual value of 0.76 for FY2024, which is 720.74% up from last year.
- According to the latest figures from Q3 2025, Cidara Therapeutics' Equity Ratio is 0.81, which was down 13.17% from 0.94 recorded in Q2 2025.
- Cidara Therapeutics' 5-year Equity Ratio high stood at 0.94 for Q2 2025, and its period low was -0.47 during Q2 2022.
- In the last 3 years, Cidara Therapeutics' Equity Ratio had a median value of 0.71 in 2024 and averaged 0.40.
- Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 292.62% in 2022, then spiked by 2,035.55% in 2024.
- Over the past 5 years, Cidara Therapeutics' Equity Ratio (Quarterly) stood at 0.29 in 2021, then plummeted by 206.16% to -0.30 in 2022, then surged by 59.72% to -0.12 in 2023, then spiked by 720.74% to 0.76 in 2024, then increased by 14.33% to 0.81 in 2025.
- Its Equity Ratio stands at 0.81 for Q3 2025, versus 0.94 for Q2 2025 and 0.74 for Q1 2025.